Terbium-161 (Tb-161), produced by Terthera through the neutron activation of highly enriched Gadolinium-160, represents the next frontier in Radioligand Therapy (RLT) and Theranostics.
This non-carrier-added (n.c.a.) lanthanide radionuclide exhibits chemical characteristics comparable to other radiolanthanides, enabling seamless integration with existing radiolabeling and production workflows.
Clinically, Tb-161 has demonstrated enhanced anti-tumor capabilities, particularly for micro-metastasized cancers, due to its higher emission of Auger and conversion electrons—offering up to a 3-fold higher cellular absorbed dose than conventional radiolanthanides.
| Specification | Details |
|---|---|
| Isotope | Terbium-161 (Tb-161) |
| Origin | Terthera – Terbium Theranostics |
| Production Method | Neutron activation of Gadolinium-160 (Gd-160) in small and medium research reactors |
| Form | Aqueous 0.05M HCl solution |
| Purity | Chemical purity > 99% (ICP-MS) / Radiochemical purity > 99% (TLC) |
| Carrier | Non-carrier-added (n.c.a.) |
| Half-life | 6.89 days |
| Beta Energy (Eβ) | 154 keV (average) |
| Gamma Energy (Eγ) | 49 keV (17%), 75 keV (10%) |
| Decay Product | Stable Dysprosium-161 (Dy-161) |
| Dosimetry | ~3× higher cellular absorbed dose compared to other radiolanthanides |
| Certification | GMP-standard production |
| Availability | Global distribution since Q1 2023 |
Effective with PSMA and SST analogues, Tb-161 demonstrates excellent bioequivalence to currently used radionuclides and improved treatment of micro-metastases.
The gamma emissions of Tb-161 enable SPECT/CT imaging with high spatial resolution, improving lesion detection and supporting personalized treatment planning.
Lower dose rates and optimized decay properties enhance safety for personnel and allow greater flexibility in clinical operations.
Prostate Cancer, Breast Cancer, Neuroendocrine Tumors, Solid Tumors